Glizid-MR 60 Tablet contains Gliclazide 60 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. It functions by stimulating pancreatic beta cells to secrete insulin, thereby improving glycemic control in patients with non-insulin-dependent diabetes. Glizid-MR 60 is formulated as a modified-release tablet, allowing for a sustained and gradual release of the active ingredient, which helps maintain stable blood glucose levels over an extended period and reduces the frequency of dosing. This medication is typically prescribed when diet, exercise, and weight reduction alone are insufficient to achieve adequate glycemic control. It is essential to monitor blood glucose levels regularly during therapy to adjust dosage accordingly and avoid hypoglycemia, a potential adverse effect characterized by symptoms such as sweating, dizziness, and confusion. Glizid-MR 60 should be used with caution in patients with renal or hepatic impairment and is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or known hypersensitivity to sulfonylureas. Patient adherence to prescribed dosing schedules and lifestyle modifications enhances therapeutic outcomes and reduces the risk of diabetes-related complications.